FDA Approves FluMist's Use in Young Children - - BioPharm International

ADVERTISEMENT

FDA Approves FluMist's Use in Young Children

BioPharm Bulletin

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2–5. Approval for the vaccine was previously limited to healthy children 5 years of age and older and adults up to age 49.

Before this approval, there were only two vaccines licensed in the US for children under the age of 5. One of the vaccines, Fluzone, is indicated for people over 6 months of age, while Fluvirin, the other vaccine, is for use in children age 4 and older.

FDA release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here